Navigation Links
Differing Ideas on Management of Alzheimer’s diseas

Doctors allege that memory clinics and drugs to retard the progress of symptoms of Alzheimer's disease are diverting resources from high quality integrated care in state-funded health services.//

The National Institute for Health and Clinical Excellence (NICE) had recommended treatments known as cholinesterase inhibitors for patients with mild-to-moderate Alzheimer's disease since 2001.

However psychiatrist Anthony Pelosi of the Hairmyres Hospital in East Kilbride, Scotland and his colleagues said that memory clinics that were initially set up to prescribe and monitor the medicines have distorted clinical priorities.

Pelosi said, "These clinics are diverting resources from high quality integrated care." He added that these drugs, which cost about 1,000 pounds per patient per year, have been found to be of marginal benefit from statistical, clinical and public health perspectives.

According to Pelosi and his colleagues although memory clinics recruited multidisciplinary staff, there is a shortage of mental health professionals in Britain. In addition the clinics do not offer care in the community for their patients as their illness progresses.

The 2001 decision by NICE stressed that further research would be needed and that the recommendation would be reviewed in several years.

In March 2005, NICE recommended these drugs must be stopped from being given to new patients because they were not cost effective. The Royal College of Psychiatrists and the Association of the British Pharmaceutical Industry condemned the decision, which NICE said was provisional and subject to consultations.

It has been estimated that 12 million people worldwide suffer from Alzheimer's which is the leading cause of dementia in the elderly.

Novartis AG's Exelon; Pfizer Inc and Eisai Co's Aricept; and Reminyl, made by Johnson & Johnson and distributed in Britain by Shire Pharmaceuticals Group are leading cholinesterase in hibitors.

Pelosi added, "Whatever the final outcome of NICE's deliberations, the human and financial resources that have become tied up in clinics organised around prescription of cholinesterase inhibitors must be diverted to old age psychiatry teams and their social care counterparts."


NLA
'"/>




Related medicine news :

1. Differing reactions to anti clotting drugs may be due to genetic variation.
2. New Ideas on Developing Thought-Controlled Artificial Limbs
3. New Modality in Migraine Management
4. Self-Management Program Beneficial for Back Pain
5. Self-Management Program Beneficial for Back Pain
6. Disease Management Programs – Effective for Heart Patient
7. Effective Management Of Heart Patients
8. Gastrin, Much More Than The Weight Management Hormone
9. Medical Management Now Available For Miscarriage
10. Early Awareness About Weight Management Needed To Tackle Lifelong Obesity
11. Exercise For Effective Pain Management In Old People
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: